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Flavonoids exhibit a variety of beneﬁcial effects in cardiovascular diseases. Although their therapeu-
tic properties have been attributed mainly to their antioxidant action, they have additional protec-
tive mechanisms such as inhibition of signal transducer and activator of transcription 1 (STAT1)
activation. Here, we have investigated the cardioprotective mechanisms of strong antioxidant ﬂavo-
noids such as quercetin, myricetin and delphinidin. Although all of them protect the heart from
ischemia/reperfusion-injury, myricetin and delphinidin exert a more pronounced protective action
than quercetin by their capacity to inhibit STAT1 activation. Biochemical and computer modeling
analysis indicated the direct interaction between STAT1 and ﬂavonoids with anti-STAT1 activity.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ischemia/reperfusion (I/R) injury leads to irreplaceable myocyte
cell loss by necrosis and apoptosis with concomitant activation of
signal transducers and activators of transcription 1 (STAT1) and
STAT3 [1], nuclear transcriptional factors with opposing effects in-
volved in the signal transduction pathways of a number of cyto-
kines and growth factors [2]. STAT1 plays a critical role in the
induction of cardiomyocyte apoptosis, whereas STAT3’s main
property is to protect cardiomyocytes from I/R injury. The result
of I/R injury in part depends on the equilibrium between I/R-elic-
ited STAT1 and STAT3 activation [3]. Recently, we have shown that
epigallocatechin-3-gallate (EGCG), the main antioxidant ﬂavonoid
present in green tea leaves, protects rat hearts from I/R-induced
damage by down-regulating STAT1 activation and suppressing
apoptosis in cardiomyocytes without affecting STAT3 activationchemical Societies. Published by E
o).
k.[4]. This strongly suggested that consumption of green tea may
be able to mediate cardioprotection and enhance cardiac function
during I/R injury. However, the mechanism of action underlying
the selective STAT1-inhibiting activity of EGCG remains largely
elusive.
Since STAT1 activation, according to some reports, may also re-
ﬂect changes in the cellular redox state [5], this raises the question
on the functional relationship between anti-STAT1 activity and the
antioxidant capacity of EGCG and other ﬂavonoids. This point is
crucial in the future development of drugs with a speciﬁc inhibi-
tory action on STAT1 activation.
All STATs, including STAT1 and 3, share common structural fea-
tures such as a DNA-binding domain, an SH2 domain and a trans-
activation domain. The SH2 domain is critically involved in the
recognition of, and interaction with, phosphotyrosine residues
present in other protein molecules. The signal transduction path-
ways in which STAT1 and STAT3 are involved also share common
intracellular mechanisms. STAT1 and 3 are rapidly phosphorylated
by the Janus tyrosine kinases JAK 1/2 and MAP serine kinase
families. Tyrosine phosphorylation is critically involved in STATlsevier B.V. All rights reserved.
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binding activity of STATs, thereby regulating gene expression.
STATs signaling is further regulated by common proteins such as
STAMs (signal-transducing adapter molecules), StIP (STAT-inter-
acting protein), the SH2B/Lnk/APS family, SOCS (suppressors of
cytokine signaling), PIAS (protein inhibitors of activated STATs)
and PTPs (protein tyrosine phosphatases) [6]. Ubiquitylation, to-
gether with sumoylation add further regulatory machineries to
the STAT1 and STAT3 activation pathways. As we recently re-
ported, I/R rapidly induces phosphorylation of tyrosine residue
701 (TYR701) and serine residue 727 (SER727) that reside in the
C-terminal transactivation domain of STAT1. All these factors need
to be considered in the identiﬁcation of STAT1 inhibiting
compounds.
In order to understand the molecular mechanisms leading to
the inhibition of STAT1 activation, we ﬁrst examined the protective
effects of strong antioxidant ﬂavonoids such as quercetin, delphin-
idin and myricetin, which are structurally highly related to EGCG,
in I/R-elicited rat heart injury. Although all exerted a protective ac-
tion against tissue damage, delphinidin and myricetin, which have
an inhibitory action on I/R-elicited STAT1 activation as well as anti-
oxidant activity, showed more pronounced protective effects than
quercetin which did not inhibit STAT1 activation. Therefore, we
further screened a number of naturally occurring antioxidant
ﬂavonoids in an in vitro cellular system to identify anti-STAT1
ﬂavonoids and then analyzed the structural features of a few of
these (delphinidin, myricetin and robinetin) to identify common
characteristics responsible for their selective inhibitory activity to-
wards STAT1. Finally, we present data indicating that anti-STAT1
ﬂavonoids exert their action by directly interacting, with high
afﬁnity, with STAT1 at sites near the SH2 domain, thereby speciﬁ-
cally and efﬁciently inhibiting I/R-induced TYR701 and SER727
phosphorylation of STAT1.2. Materials and methods
2.1. Animal model
Male Sprague–Dawley rats were obtained from Charles River
UK (Margate, UK) and were cared for in accordance with The Guid-
ance on the Operation of the Animals (Scientiﬁc Procedures) Act
1986 and under institutional license from the Government Home
Ofﬁce (London, UK).
2.2. Isolation and treatment of isolated cardiac myocytes
Ventricular myocytes isolated from neonatal Sprague–Dawley
rats were transferred onto six-well gelatin coated plates at a den-
sity of 105 cells/well. When a conﬂuent monolayer of spontane-
ously beating myocytes was formed, cardiac myocytes were
subjected to 4 h hypoxia and 16 h reoxygenation as previously de-
scribed [7]. Delphinidin, myricetin or quercetin (10, 25 and 50 lM;
Extrasynthese, Genay, France) were added to cultured myocytes
2 h prior to the hypoxic injury and during reoxygenation.
2.3. Cell death assessment in isolated cardiac myocytes
Cell death was evaluated as described previously [8,9]. Single
cell suspensions were prepared and mixed with Annexin V FITC,
at a ﬁnal concentration of 1 lg/ml (BD Biosciences, San Jose, CA,
USA), and propidium iodide, at a ﬁnal concentration of 1 lg/ml
(Sigma–Aldrich, St. Louis, MO, USA), in the presence of 1.8 mM cal-
cium chloride. Cells were then incubated at room temperature for
15 min and immediately analyzed on a Beckman Coulter XL ﬂow
cytometer.2.4. Perfusion of isolated rat hearts
Rats, weighing 250–300 g, were anesthetized by sodium pento-
barbital (6 mg/kg administered intraperitoneally) and killed by
decapitation. The hearts were removed, immersed in an ice-cold
modiﬁed Krebs-Hensleit buffer solution and subsequently per-
fused by the non-recirculating Langendorff technique at a constant
ﬂow of 11 ml/min [10]. The heart rate was continuously main-
tained at 300 bpm by electrical pacing and the left ventricular wall
was kept at a steady temperature of 37 C.
2.5. Treatment protocols
After a period of stabilization of 30 min, the isolated hearts
were randomly divided into eight groups (A, B, C, D, E, F, G and
H) of at least eight hearts each. Groups A and B were aerobically
perfused for 60 min, without (group A) or with the addition of del-
phinidin (group B1), myricetin (group B2) or quercetin (group B3)
(10 lM) to the perfusate respectively. Groups C, D, E, F were ex-
posed to 30 min of regional ischemia and 2 h of reperfusion, with-
out (group C) or with (groups D, E and F) pretreatment with either
delphinidin, or myricetin or quercetin, respectively. Group G was
infused for 1 h with recombinant human interferon-c (IFN-c)
(100 units/ml) (R&D Systems, Minneapolis, MN), with (group G2)
o without (group G1) pretreatment with a speciﬁc and irreversible
inhibitor of caspase-8 (Z-IEDT.fmk), at a dose of 0.07 lM (Calbio-
chem, EMD Biosciences Inc., San Diego, CA, USA). Group H1 re-
ceived a 1 h infusion of methyl-2-cyano-3,12 dioxoolean-1,9
diene-28-oate (CDDO-Me) (0.05, 0.1, 0.5 lM), which was either gi-
ven alone or preceded by treatment with the individual ﬂavonoids
at the given concentrations (groups H2, H3 and H4).
2.6. Regional ischemia
After stabilization, the left coronary artery of isolated rat hearts
was surgically occluded for 30 min and subsequently reperfused
for 60 min [10].
2.7. Infarct size measurement
Measurement of risk area and infarct size was performed by tri-
phenyl-tetrazolium chloride (TTC) staining as previously reported
[11]. The left ventricular (LV) infarct zone was determined by com-
puterized planimetry and expressed as a percentage of the in-
farcted area within the myocardium at risk.
2.8. Left ventricular pressure
To obtain an isovolumetrically beating preparation, a latex bal-
loon ﬁlled with saline, connected by a catheter to a Statham trans-
ducer (P 23 XL), was inserted into the left ventricle through an
atriotomy and secured by a suture around the atrioventricular
groove. The balloon was inﬂated to provide an end-diastolic pres-
sure <1.0 mm Hg [12].
2.9. Assay of creatine phosphokinase in the coronary efﬂuent
During each perfusion, the coronary efﬂuent was collected at
different time points in chilled glass vials and promptly assayed
for CPK activity by spectrophotometry [13,14].
2.10. Caspase activity assay
Cardiac activation of caspase-3, caspase-8 and caspase-9 was
evaluated in tissue extracts using commercial kits (Biovision;
Mountain View, CA, USA) [8,15]. Enzyme reactions were performed
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50 lM AFC (7-amino-4-triﬂuoromethyl coumarin)-conjugated
substrates speciﬁc for either caspase-3, -8 and -9. Samples were
read in a ﬂuorimeter equipped with a 400-nm excitation and a
505-nm emission ﬁlter.
2.11. Determination of tissue malondialdehyde (MDA) concentration
Levels of MDA were measured in cardiac tissue as described
previously [11].
2.12. Preparation and pre-treatment of tissue sections
Once removed from the perfusion apparatus, the hearts were
cross-sectioned from the apex to the atrioventricular groove into
four 2.5 mm thick slices, which were subsequently placed in 4%
formaldehyde and embedded in molten parafﬁn [8,10,12,14].
2.13. TUNEL
TUNEL staining was performed on myocardial sections using a
commercial kit (Boehringer Mannheim; Lewes, Sussex, UK) [10,12].
2.14. Additional staining
Following TUNEL staining, a previously described multiple step
immunocytochemical procedure was used [10,12]. Myocardial sec-
tions were labeled with either anti-desmin or anti-von Willebrand
factor antibodies, in order to selectively identify myocytes and
endothelial cells respectively. After incubation with speciﬁc sec-
ondary antibodies, the slides were counterstained with propidium
iodide and ﬁnally examined by confocal ﬂuorescent microscopy.
Data are expressed as the means of 12–15 high power ﬁelds ±S.D.
2.15. MDA-MB-231 cell line
The human breast cancer cell line MDA-MB-231 was cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; BioWhittaker,
Cambrex Bio Science, Belgium) supplemented with 10% fetal bo-
vine serum (FBS; BioWhittaker, Cambrex Bio Science, Belgium),
100 UI/ml penicillin, 100 lg/ml streptomycin, 2 mM glutamine,
40 lg/ml gentamicin, in a humidiﬁed atmosphere of 95% air, 5%
CO2 at 37 C.
2.16. Electrophoretic mobility shift assay
Eight micrograms of the nuclear extract prepared from MDA-
MB-231 cells according to Osborn et al. [16] were incubated for
20 minutes at room temperature with 2–5  104 cpm of a 32P-la-
beled double-stranded oligonucleotides containing the STAT1
binding site (sis-inducible factor-binding recognition element,
SIE/m67) from the c-fos promoter (50-gtcgaCATTTCCCGTAAATCg-
30) (Promega, Milan, Italy), in a 15 ll reaction mixture containing
20 mM Hepes, pH 7.9, 50 mM KCl, 0.5 mM dithiothreitol, 0.1 mM
EDTA, 2 lg of poly(dI–dC), 1 lg of salmon sperm DNA, and 10%
glycerol. Products were fractionated by electrophoresis on a non-
denaturing 5% polyacrylamide gel.
2.17. Western blot analysis
Cell or tissue extracts were lysed on ice for 15 min with 20 mM
HEPES, pH 7.4, 420 mM NaCl, 1% Nonidet P40, 1 mM EGTA, and
1 mM EDTA. After centrifugation for 15 min at 12000 rpm, proteins
(40 lg/lane) were fractionated by electrophoresis on 7.5% SDS–
polyacrylamide gel and electroblotted onto a PVDF membrane
(Immobilon P, Millipore, Bedford, MA, USA). Membranes wereincubated with antibody anti-STAT1, anti-STAT3, anti-active-cas-
pase-3; anti-FAS; anti-actin (Santa Cruz Biotechnology, CA, USA),
anti-phosphoSTAT1Y701 (New England Biolabs, Hitchin, England)
or anti-phosphoSTAT3Y705 (Cell Signaling Technology, MA, USA),
and, after washing, with an anti-rabbit IgG-peroxidase conjugate
(AmershamBiosciences, Little Chalfont, Buckinghamshire, UK).
The immunoreactive proteins on the blot were detected by an en-
hanced chemiluminescence detection system (ECL) (Amersham
Biosciences AB, Uppsala, Sweden). Following the analysis of phos-
phorylated STAT1 or STAT3, the blots were stripped and reprobed
with anti-STAT1 or anti-STAT3 antibody.
2.18. Surface plasmon resonance analysis
Interaction of STAT1 with each ﬂavonoid was examined by sur-
face plasmon resonance using a BiaCore 2000 biosensor system.
STAT1 protein (Biosurce, Camarillo, CA, USA), corresponding to
15000–18500 as resonance units (RU), was immobilized on the
carboxymethylated sensor chip, CM5, by an amine coupling reac-
tion kit (BIAcore Inc., Uppsala, Sweden) according to the manufac-
ture’s instructions. Each ﬂavonoid in HBS-EP buffer (BIAcore Inc.)
was injected into the ﬂow cell containing immobilized STAT1. A
ﬂow cell without STAT1 was used as control. Appropriate concen-
tration ranges of ﬂavonoids were determined from anticipated pre-
liminary experiments. Sensorgrams for each ﬂavonoid were
analyzed with BIA evaluation software and BIA simulation soft-
ware (BIAcore Inc.).
2.19. Computer modeling
Searching for putative interaction sites was carried out by using
Q-siteﬁnder [17] (http://www.bioinformatics.leeds.ac.uk/qsite-
ﬁnder/) on the X-ray structure of STAT1 (pdb entry 1yvl.pdb [18].
Docking simulations were carried out using AutoDock v3.0.5
[19] and Gold v3.0 [20] programs which were both recently re-
ported to be the most accurate software for this purpose [21–23].
Both docking algorithms were used with full ﬂexibility of the li-
gands but with limited or no protein ﬂexibility. The geometry of
the ligands was obtained by minimization with the semi empirical
method AM1 by using the Gaussian03 [24] program. ADTOOLS, the
graphical interface of AutoDock was used for adding the polar
hydrogens for docking calculations and for assigning the atomic
charges of the protein. The protein and the ligands were prepared
with Chimera-1.2255 [25] and VegaZZ 2.0.7 [26] for Gold.
Calculations with AutoDock were performed using a particu-
larly accurate procedure using the Lamarckian algorithm with a
population size of 100, a number of energy evaluations of
2.0  106, a generation number of 27000, and a mutation and
crossover rates of 0.02 and 0.8, respectively. The energies were
evaluated by using atomic afﬁnity potentials for each atom type
of the ligand calculated by AutoGrid v3.0.5 Furthermore, the num-
ber of runs was set to 100 to explore a large number of poses of the
highest afﬁnity and the Solis and Wets algorithm was used to relax
the best 10% of the obtained conformations. Gold calculations were
performed using the Goldscore scoring function. The default set-
ting parameters of the genetic algorithm were used. The best 20
orientations were analyzed in detail.
2.20. Statistics
Data are expressed as means ± S.D. Single-factor one-way anal-
ysis of variance (ANOVA) was performed for each group of treat-
ments and signiﬁcance was assumed when P < 0.05. Differences
among means were compared within the treatment groups using
Student’s t -test with a signiﬁcance level of P < 0.05. Experi-
ments were repeated at least three times. With regard to the
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time as the covariate and post hoc analyses, were used to test
the principal component with contrast. The Bonferroni correction
was then applied and P values <0.05 were considered signiﬁcant.3. Results
3.1. Cardioprotection by myricetin, delphinidin and quercetin
We ﬁrst examined the effect of myricetin, delphinidin and quer-
cetin, three strong naturally occurring antioxidant ﬂavonoids, in
neonatal cardiomyocytes under hypoxic conditions. After exposure
to 4 h hypoxia followed by 16 h reoxygenation, the addition of
these ﬂavonoids, 2 h before the onset of the ischemic insult, re-
duced the extent of both necrotic and apoptotic cell death
(Fig. 1A). The protection afforded by myricetin and delphinidin
was signiﬁcantly stronger than that provided by quercetin.
Secondly, to extend these ﬁndings to ex vivo conditions, we
examined the effect of these ﬂavonoids in the Langendorff perfused
rat heart. Myricetin, delphinidin and quercetin, infused for 1 h be-
fore the onset of ischemia and during reperfusion, signiﬁcantly re-
duced infarct size (Fig. 1B), as well as the post-ischemic release of
creatine phosphokinase (CPK) (Fig. 1C). In line with the in vitro
data, quercetin-mediated cardioprotection was signiﬁcantly less
than that provided by either myricetin or delphinidin.
3.2. Effect of ﬂavonoids on hemodynamic, histological and biochemical
parameters in the heart after I/R
To examine the functional implications of ﬂavonoid-mediated
cardioprotection, we also evaluated the changes in left ventricularFig. 1. Effect of delphinidin myricetin and quercetin against I/R-induced heart injury. (A
neonatal cardiac myocytes. Values are averages of three independent experiments ±S
expressed as a percentage of myocardial risk zone. Values are averages of three independe
pre-treatment with ﬂavonoids. Values are averages of three independent experiments
treated group, as depicted. (D) Percentages of TUNEL and cleaved active caspase-3 (Casp3
in I/R hearts pretreated ex vivo with either delphinidin, or myricetin, or quercetin. Va
ischemic control hearts or other I/R.systolic pressure (LVSP) and left ventricular end diastolic pressure
(LVEDP) in the isolated rat heart exposed to I/R injury. The pre-
ischemic infusion of the three ﬂavonoids, which did not alter the
baseline LVSP and LVEDP values, signiﬁcantly improved the post-
ischemic recovery of cardiac function, with amelioration of both
LVSP and LVEDP, and was proportional to the degree of cardiopro-
tection afforded by the three ﬂavonoids (Fig. 2A–D).
In myocardial tissue sections from hearts infused with either
myricetin, delphinidin, or quercetin, the occurrence of apoptosis
was signiﬁcantly reduced. Again, the reduction of apoptosis pro-
duced by myricetin or delphinidin was signiﬁcantly greater than
that induced by quercetin (Fig. 1D).
Since generation of reactive oxygen species (ROS) has been
implicated in the induction of apoptosis not only triggering directly
the mitochondrial pathway, but also leading indirectly to activa-
tion of the death-receptor-mediated pathway [27], we measured
the intracellular concentration of malondialdehyde (MDA), a mar-
ker of lipid peroxidation, which occurs as a result of the damaging
effects of ROS in the intact rat heart [11]. We found that MDA con-
centration in the area at risk of I/R hearts was approximately three
times higher than in control hearts. Infusion of three ﬂavonoids re-
duced MDA concentration close to control levels, conﬁrming that
free radical production had been successfully inhibited to an equiv-
alent extent by all ﬂavonoids. This ensures that discrepancies in
antioxidant efﬁcacy cannot account for the different degree of pro-
tection observed between the three ﬂavonoids (Fig. 3).
3.3. Effect of ﬂavonoids on protection against I/R-induced apoptosis in
the heart
As previously stated, we have documented that cardiac
ischemia results in STAT1 activation, with subsequent myocyte) Quantiﬁcation of necrosis and apoptosis by ﬂow cytometry in primary cultures of
.D. *P < 0.05; **P < 0.01 vs. ischemic/reperfused control (Ctrl I/R). (B) Infarct size,
nt experiments ±S.D. (C) Post-ischemic release of CPK in I/R hearts with and without
±S.D. *P < 0.05; **P < 0.01 vs. ischemic control hearts or other ischemic/reperfused
) myocyte colocalization in control I/R-untreated or -I/R exposed heart (CtrI/R), and
lues are averages of three independent experiments ±S.D. *P < 0.05; **P < 0.01 vs.
Fig. 2. Effect of delphinidin myricetin and quercetin against I/R induced heart dysfunction. Changes in left ventricular systolic pressure (LVSP) and left ventricular end
diastolic pressure (LVEDP) in the control I/R (Ctrl I/R) heart (A) and in the isolated heart perfused with delphinidin (B), myricetin (C) and quercetin (D) for 1 h before
undergoing I/R injury. Values are averages of three independent experiments ±S.D.
Fig. 3. Anti oxidant action of delphinidin myricetin and quercetin in the I/R treated heart. Intracellular concentration of malondialdehyde (MDA) in normoxic (ctrl) and I/R
control hearts (Ctrl I/R) and in rat hearts treated for 1 hour with either delphinidin, or myricetin, or quercetin before exposure to I/R. Values are averages of three independent
experiments ± S.D.
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following increased FAS ligand and FAS receptor expression.
Myricetin and delphinidin signiﬁcantly reduced the I/R-induced
tyrosine phosphorylation of STAT1, though not that of STAT3. Both
ﬂavonoids also reduced substantially the expression level of FAS
and the cleavage of caspase-3 (Fig. 4A and B). Conversely, infusion
of quercetin reduced caspase-3 cleavage, though less dramatically
than myricetin and delphinidin, but had no effect on STAT1 and
STAT3 phosphorylation or FAS expression (Fig. 4C).
To further investigate the antiapoptotic mechanisms of action
of delphinidin, myricetin and quercetin, we assessed the activationof caspase-8 and caspase-9 after ﬂavonoid infusion. Caspase-9 acti-
vation was particularly pronounced in hearts exposed to I/R and
was signiﬁcantly reduced by all three ﬂavonoids. Although cas-
pase-8 activation was signiﬁcantly reduced by myricetin and del-
phinidin, it was unaffected by quercetin (Fig. 4D), suggesting that
myricetin and delphinidin inhibit apoptosis by reducing the activa-
tion of the apical caspases, while quercetin is only effective in
reducing apoptosis initiated by mitochondrial injury. Together,
these data are consistent with the ability of myricetin and delphin-
idin to inhibit the activation of STAT1 and therefore decrease the
expression of components of the FAS death receptor pathway.
Fig. 4. Effect of delphinidin myricetin and quercetin on STAT1 activation in the I/R treated heart. (A–C) Western blot analysis of protein extracts from control, I/R control
hearts and hearts treated with ﬂavonoids. Western blots were performed with speciﬁc antibodies against STAT1 and phosphorylated STAT1 (pSTAT1); STAT3 and
phosphorylated STAT3 (pSTAT3); cleaved caspase-3 and FAS. Results are representative of three independent experiments. (D) Caspase-3, ( ), -8 ( ) and -9 () enzymatic
activity in whole tissue extracts from control hearts and hearts made ischemic and reperfused with or without ex vivo treatment with either delphinidin, or myricetin, or
quercetin. Fold-increase in caspase activity was determined by comparing ﬂuorescence of AFC in control and treated hearts with buffer perfused control. Values are averages
of three independent experiments ±S.D. **P < 0.01 vs. ischemic control hearts. (E) Caspase-3, ( ), -8 ( ) and -9 () enzymatic activity in whole tissue extracts from
normoxic control hearts and rat hearts infused with either IFN-c or CDDO-Me. Infusion with IFN-cwas performed alone or preceded by infusion of either a speciﬁc caspase-8
inhibitor or infusions of delphinidin, myricetin or quercetin. In another set of experiments, CDDO-Me infusion was performed alone or after infusions of delphinidin,
myricetin or quercetin. Fold-increase in caspase activity was determined by comparing ﬂuorescence of AFC in control and treated hearts with buffer perfused control. Values
are averages of three independent experiments ±S.D. *P < 0.05, **P < 0.01 vs. rat hearts infused with either IFN-c or CDDO-Me.
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caspase-8 but retains the ability to inhibit caspase-9 activation fol-
lowing mitochondrial damage due to its antioxidant properties.
To further explore and distinguish the mechanisms of action of
myricetin and delphinidin compared with quercetin, we infused
IFN-c into isolated rat hearts. While myricetin and delphinidin pre-
vented IFN-c-elicited activation of caspase-8, as well as caspase-9,
quercetin did not affect their activation. Furthermore, none of the
three ﬂavonoids reduced caspase-9 activation following 1 h infu-
sion of CDDO-Me, a synthetic oleanolic acid derivative that po-
tently activates the mitochondrial pathway without enhancing
free radical generation [28], suggesting that their antioxidant
activity represents the main mechanism by which they inhibit acti-
vation of caspase-9 (Fig. 4E).
3.4. Structural characteristics of anti-STAT1 ﬂavonoids
Once we had ascertained that the more pronounced protective
effect of myricetin and delphinidin over quercetin was correlated
with the anti-STAT1 activity of the former two, we performed a
structure activity relationship study in order to identify the most
important chemical groups responsible for this activity. We tested
26 ﬂavonoids from different chemical families (Fig. 5) for their
ability to inhibit STAT1 DNA-binding by electromobility shift assay
(EMSA) in the cell line MDA-MB-231. Of these, and in agreement
with our previous data, only myricetin and delphinidin, togetherwith robinetin, exerted a dose-dependent inhibitory action on
IFN-c-induced STAT1 DNA-binding, with EC50 values of 5, 20 and
35 lM, respectively (Fig. 6A). The same three compounds also re-
duced IFN-c-induced STAT1 TYR701 phosphorylation in a concen-
tration-dependent manner without modifying the amounts of total
STAT1 protein (Fig. 6B), further conﬁrming the data from the heart
studies. These results indicate the importance of the presence of
three hydroxyl groups in the 30, 40, 50 positions in the B ring of
STAT1 inhibitory ﬂavonoids (Fig. 5). Furthermore, the absence of
the hydroxyl group in the 3 position of the C-ring as in tricetin
or the glycosylation of this group as in myricitrin or myrtyllin leads
to the complete loss of activity. The antioxidant nature of ﬂavo-
noids is deﬁned mainly by the presence of the cathecol B ring
and of 2, 3 unsaturation in conjugation with a 4-oxo function in
the C-ring [29]. Therefore, these data, in line with the in vivo re-
sults, indicate that inhibitory action of anti-STAT1 ﬂavonoids
should not be attributed simply to their antioxidant activity.
3.5. Direct interaction between anti-STAT1 ﬂavonoids and STAT1 SPR
study
Thereafter, we hypothesized that anti-STAT1 ﬂavonoids exert
their action by directly interacting with the STAT1 protein. We
evaluated by surface plasmon resonance (SPR) the interaction be-
tween immobilized STAT1 and a number of ﬂavonoids. Analysis
of sensograms (Fig. 7A and B) indicates not only a direct interaction
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also the presence of two putative sites of interaction on STAT1. The
very low KD value for one site of myricetin, delphinidin, and rob-
inetin for binding to STAT1 indicated a strong afﬁnity for this pro-
tein (Fig. 4D). These data are in line with our previous results in cell
lines (Fig. 6A and B). Furthermore, all other antioxidant ﬂavonoids
examined show much lower or no afﬁnity toward STAT1 in accor-
dance with results described above.
3.6. Computer modeling analysis
We also analyzed the direct interaction between ﬂavonoids and
STAT1 by molecular modeling experiments with the ﬁrst part of
the study designed to determine the probable site(s) of interaction
of the ﬂavonoids with the protein. Indeed, neither experimental
nor theoretical determinations of the position of this site(s) are
presently available. Using different programs to detect binding sitecavities in proteins, three major putative sites were identiﬁed. Two
of the sites are located at the interface between the SH2 and
the linker domains, and the third is in the DNA-binding domain.
The third binding site was ignored in this study since the most sta-
ble docked orientations in this site were yet signiﬁcantly higher in
energy than for sites 1 and 2 (site 1 10.90, site 2 10.84, and site
38.96 kcal/mol). This observation could be related with an earlier
study reporting that EGCG blocked the phosphorylation of STAT1
for recombinant receptor with truncated DNA domain [30]. The
detection of the two remaining sites (sites 1 and 2) is in agreement
both with previous experimental studies [31,32] which demon-
strated the importance of the SH2-domain in the STAT-JAK propa-
gation signal and with above-mentioned results on the presence of
two anti-STAT1 ﬂavonoid-binding sites on STAT1 (Fig. 7D). The
presence of these two probable binding sites at the SH2 domain
is also in agreement with the ﬁndings of Mao et al. [18] who re-
ported that the phosphopeptide pYDHPH (derived from the a chain
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Fig. 6. Myricetin, delphinidin, and robinetin inhibit STAT1 activation. (A) Nuclear proteins of cells were analyzed by EMSA. Histograms of these gels are also presented. The
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of STAT1 located in a ﬂexible region of the SH2-domain.
To better understand the nature of ﬂavonoid-STAT1 interactions
at the molecular level, docking calculations were performed. Sim-
ulations predict good binding afﬁnities for most of the ligands at
both sites 1 and 2. The detailed analysis of the best predicted
orientations of the ligands in the different cavities shows that the
hydroxyl groups of ring B are very important for stabilizing ﬂavo-
noid-STAT1 complexes which agrees with the ligand based analysis
mentioned above. These groups are oriented towards the interior of
the cavity either in site 1 or 2 for the three active anti-STAT1 ﬂavo-
noids, and interact with residues TRP573 and GLN518 on site 1
(Fig. 7E) and HIS568 and LEU639 on site 2 (Fig. 7G). However, for
non-anti-STAT1 ligands, these groups are oriented towards the
exterior of the cavity, interacting with other residues – e.g. querce-
tin interacts with ARG586 and PHE581 in site 1 (Fig. 7F), and withSER640 in site 2 (Fig. 7H). These differences in binding orientations
may explain the weaker inhibitory effect of quercetin.4. Discussion
4.1. Role of myricetin and delphinidin in the protection of the heart
from I/R-injury
Our recent reports indicated that EGCG, a potent antioxidant
ﬂavonoid present in green tea leaves, exerts an inhibitory action
towards IFN-c-elicited activation of STAT1 in a number of cell lines
[33] and efﬁciently protects against I/R-induced injury in the heart
[4], suggesting that consumption of green tea may be able to
mediate cardioprotection and enhance cardiac function during I/
R injury. The present study extends this notion.
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examined (delphinidin, myricetin and quercetin), consistent with
their strong antioxidant activity, are able to inhibit the intrinsic
pathway of cardiomyocyte apoptosis in which mitocondrial integ-
rity is crucial. This is in line with the widely reported beneﬁcial ac-
tion of antioxidant ﬂavonoids towards inﬂammatory diseases [34].
However, the critical ﬁnding of the present study is that, compared
to quercetin, myricetin and delphinidin, by attenuting I/R-inducedSTAT1 activation, suppress cardiomyocyte apoptosis more efﬁ-
ciently by selectively interfering with the extrinsic pathway in
which STAT1-dependent FAS/FAS ligand expression plays a critical
role. Notably, we observed a more pronounced protective effect of
myricetin and delphinidin towards both heart tissue injury and
hemodynamic impairment which was strictly correlated with their
speciﬁc anti-STAT1 activity, suggesting that STAT1 could be a rele-
vant target for protective treatment of I/R injury in the heart.
540 T.M. Scarabelli et al. / FEBS Letters 583 (2009) 531–5414.2. Mechanism of inhibition of STAT1 activation by anti-STAT1
ﬂavonoids
It is striking that among a number of ﬂavonoids examined in
this study, only those (myricetin, delphinidin and robinetin) with
a particular structural feature such as the presence of three hydro-
xyl groups in the B ring and one in the 3 position of the C ring, exert
strong anti-STAT1 activity. Our in vitro and in vivo results indicate
further that the inhibitory action of anti-STAT1 ﬂavonoids should
not be attributed solely to their antioxidant activity. Since tricetin,
myricitrin and myrtyllin have no inhibitory action on IFN-c-elic-
ited STAT1 activation, and are unable to directly interact with
STAT1, position 3 of the C-ring of anti-STAT1 ﬂavonoids is therefore
critical for their speciﬁc action. Although the docking analysis data
would support this assumption, a more detailed study that takes
into account the ﬂexibility of the protein is required for a deeper
understanding of the inhibitory mechanism.
The capacity of anti-STAT1 ﬂavonoids to directly interact with
STAT1 with high afﬁnity at critical sites near the SH2 domain
underlines the novel mechanism leading to the efﬁcient, speciﬁc
inhibition of STAT1 activation. In particular, the very high afﬁnity
of these ﬂavonoids towards putative binding site 1 is in line with
the speciﬁcity of their action towards the STAT1 pathway shown
in this study. Indeed, STAT3, having a slightly different SH2 domain
with respect to that of STAT1, was not inhibited by anti-STAT1
ﬂavonoids in I/R injury, adding further support to the above-men-
tioned mechanism. This may also explain how anti-STAT1 ﬂavo-
noids disturb I/R-elicited phosphorylation of both TYR701 and
SER727, both of which are situated near putative anti-STAT1 ﬂavo-
noid binding sites. Furthermore, the highly efﬁcient effect of anti-
STAT1 ﬂavonoids in protecting the heart from I/R-induced injury is
in line with their very high afﬁnity towards STAT1 (especially at
putative binding site 1, KD  20 nM). The present study may also
serve as a starting point for further development of phytochemi-
cal-derived compounds capable of selectively inhibiting STAT1
activation to be tested in the prevention and/or treatment of
inﬂammatory diseases in which STAT1 plays a critical role.
In conclusion, this report indicates that, at a molecular level,
among a number of antioxidant ﬂavonoids examined, only myrice-
tin, delphinidin and robinetin with a common structural feature
including the presence of three hydroxyl groups in the B ring and
of the hydroxyl group in the 3 position of C-ring are able to interact
directly with STAT1 with high afﬁnity. Therefore, at the tissue le-
vel, these have a more pronounced protective action against I/R-in-
duced heart injury in which STAT1 plays a critical role in activating
the extrisic apoptotic pathway. The consumption of foods contain-
ing ﬂavonoids with structural features of myricetin, delphinidin
and robinetin, together with green tea containing EGCG, may rep-
resent an important new preventive treatment of cardiovascular
diseases.
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